To continue reading this article, sign up for FREE to
Membership is FREE
and provides you with
instant access
to email newsletters, digital publications, our full content catalogue & more...
Evotec Announces Phase I Initiation with P2X7 Antagonist
Evotec AG has announced that Phase I clinical studies for its proprietary, small molecule P2X7 receptor antagonist have been initiated.
The P2X7 receptor is an ATP-gated ion channel primarily expressed on cells of the immune system and is thought to play an important role in inflammatory processes through the regulation of a number of proinflammatory cytokines. P2X7 receptor antagonism may provide a novel approach to the treatment of rheumatoid arthritis and other inflammatory conditions, which affect millions of individuals.
The first Phase I study is a double-blind and placebo-controlled single ascending dose study in healthy male volunteers to evaluate the compound’s safety, tolerability, pharmacokinetic profile and pharmacodynamic effects after oral administration.
Add Technology Networks as a preferred Google source to see more of our trusted coverage.
